Wall Street brokerages predict that BioScrip Inc (NASDAQ:BIOS) will post sales of $170.23 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioScrip’s earnings, with the lowest sales estimate coming in at $164.00 million and the highest estimate coming in at $179.94 million. BioScrip reported sales of $217.81 million in the same quarter last year, which indicates a negative year over year growth rate of 21.8%. The firm is scheduled to announce its next earnings results on Thursday, May 3rd.
On average, analysts expect that BioScrip will report full year sales of $170.23 million for the current year, with estimates ranging from $698.16 million to $716.50 million. For the next financial year, analysts anticipate that the business will post sales of $766.20 million per share, with estimates ranging from $747.04 million to $778.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow BioScrip.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Thursday, March 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The company had revenue of $182.50 million for the quarter, compared to the consensus estimate of $171.35 million. The company’s revenue for the quarter was down 24.0% compared to the same quarter last year. During the same period last year, the business earned ($0.06) EPS.
Several brokerages recently issued reports on BIOS. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a report on Saturday, March 3rd. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. SunTrust Banks set a $4.00 target price on BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Craig Hallum restated a “buy” rating and issued a $3.50 target price on shares of BioScrip in a report on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. BioScrip presently has a consensus rating of “Hold” and an average price target of $3.45.
Shares of NASDAQ BIOS traded up $0.19 during mid-day trading on Wednesday, hitting $2.64. The company had a trading volume of 1,113,475 shares, compared to its average volume of 958,097. The company has a market cap of $312.86, a price-to-earnings ratio of -6.00 and a beta of 0.11. BioScrip has a 12 month low of $1.35 and a 12 month high of $3.39. The company has a current ratio of 1.79, a quick ratio of 1.42 and a debt-to-equity ratio of -5.65.
Several hedge funds have recently modified their holdings of the company. Gotham Asset Management LLC bought a new position in BioScrip during the fourth quarter valued at about $114,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of BioScrip in the 3rd quarter valued at approximately $114,000. Highbridge Capital Management LLC bought a new stake in shares of BioScrip in the 3rd quarter valued at approximately $153,000. MetLife Investment Advisors LLC bought a new stake in shares of BioScrip in the 4th quarter valued at approximately $174,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of BioScrip by 9.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after purchasing an additional 8,914 shares during the period. Institutional investors and hedge funds own 84.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/170-23-million-in-sales-expected-for-bioscrip-inc-bios-this-quarter.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Get a free copy of the Zacks research report on BioScrip (BIOS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.